Trial for Application of Laparoscopic Total Gastrectomy With Lymph Node Dissection for Gastric Cancer (KLASS-06)

Gastric Cancer Clinical Trial

Official title:

Multicenter Randomized Controlled Trial for Application of Laparoscopic Total Gastrectomy With Lymph Node Dissection for Gastric Cancer (KLASS-06)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03385018
• Other study ID #: 4-2017-0940
• Status: Recruiting
• Phase: N/A
• Start date: April 5, 2018
• Est. completion date: December 31, 2027

Study information

• Verified date: March 2019
• Source: Yonsei University
• Contact: Woo Jin Hyung, MD, PhD
• Phone: +82-2-2228-2100
• Email: wjhyung[@]yuhs.ac
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Although Laparoscopic gastrectomy for both early and locally advanced gastric cancer has gained popularity, the use of laparoscopic total gastrectomy for proximal advanced gastric cancer is still limited to some experienced surgeons, because of its technical difficulties in D2 lymph node dissection and anastomoses.

Some retrospective and cohort studies regarding laparoscopic total gastrectomy with lymph node dissection suggested the likelihood of application of laparoscopic surgery for proximal gastric cancer. However, there has been no randomized clinical trial comparing results of laparoscopic total gastrectomy with D2 lymph node dissection with open conventional surgery.

Therefore, we aimed to verify the efficacy of laparoscopic total gastrectomy with D2(D2-10) lymph node dissection, technical and oncologic safety compared with open surgery via multicenter randomized clinical trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 772
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients who are over 20 and below 80 years old

• Patients who have performance status of ECOG 0 or 1

• Patients with American Society of Anesthesiology score of class I to III

• Patients who are diagnosed with gastric adenocarcinoma not involving Z-line by endoscopy with biopsy

• Patients with tumors which can be curatively resected by total gastrectomy with lymph node dissection based on preoperative study

• Patients who have primary gastric carcinoma invaded into over muscle propria, and not into adjacent organ in preoperative studies (cT2 ~ cT4a)

• Patients who have no metastasis to lymph nodes or limited metastasis to perigastric lymph node metastasis in preoperative studies (cN0 ~ cN2)

• Patients who agree with participating in the clinical study with informed consents

• Patients who can be followed for at least 3 years after study enrollment

Exclusion Criteria:

• Patients who have possibility of distant metastasis in preoperative studies

• Patients who have history of gastric resection with any cause

• Patients who have complications (bleeding or obstruction) of gastric cancer

• Patients who are treated by chemo(radio)therapy or endoscopic submucosal dissection for gastric cancer

• Patients who are diagnosed and treated with other malignancies within 5 years

• Vulnerable patients

• Patients who participating or participated in other clinical trial within 6 months

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Procedure:
• Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach
Total gastrectomy with D2(D2-10) lymph node dissection by laparoscopic approach The number of trocars is 6 or less Roux-en-Y esophagojejunostomy with any stapling method Enough(negative) margin from tumor LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined Washing cytology Frozen biopsy for surgical margin at surgeons discretion Complete omentectomy for grossly serosa-involved tumor Combined organ resection only in cholecystectomy and splenectomy Indwelling nasogastric tube and drainage catheter at surgeons discretion D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection
• Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach
Total gastrectomy with D2(D2-10) lymph node dissection by open conventional approach Roux-en-Y esophagojejunostomy with any stapling method Enough(negative) margin from tumor LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined Washing cytology Frozen biopsy for surgical margin at surgeons discretion Complete omentectomy for grossly serosa-involved tumor Indwelling nasogastric tube and drainage catheter at surgeons discretion D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection

Locations

Country	Name	City	State
Korea, Republic of	Department of Surgery, Yonsei University College of Medicine, Seoul, Korea	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	3 year relapse-free survival	Non-inferiority of 3 year relapse-free survival rate after laparoscopic radical total gastrectomy and lymphadenectomy for locally advanced gastric cancer comparing with open conventional surgery.; The "event" of relapse-free survival is defined as "recurrence" after 4 weeks of operation.; The "censoring" is defined as non-traceable patient who cannot be confirmed with recurrence or patient who are alive without recurrence until follow-up.; The "relapse-free survival time" is defined as the time from surgery to "event" or "censoring".	3 years after surgery
Secondary	3 year overall survival rate		3 years after surgery
Secondary	5 year relapse-free and overall survival		5 years after surgery
Secondary	Morbidity (early period)		from Operation day until POD 21
Secondary	Morbidity (late period)		from POD (Post-Operative Day) 22 until 5 years after surgery
Secondary	Mortality	death with any cause	at POD 30
Secondary	Mortality	death with any cause	at POD 90
Secondary	Quality of life(EORTC QLQ-C30)	Quality of life measured by EORTC QLQ-C30(Version 3) The questionnaire was designed to measure cancer patients' physical, psychological and social functions. The questionnaire is composed of 5 multiitem scales (physical, role, social, emotional and cognitive functioning) and 9 single items (pain, fatigue, financial impact, appetite loss, nausea/vomiting, diarrhea, constipation, sleep disturbance and quality of life).	at POD 21
Secondary	Quality of life(EORTC QLC STO22)	Quality of life measured by EORTC QLC STO22. The EORTC QLQ-STO 22 module contains 22 items in a similar layout and response format to the EORTC QLQ-C30. The hypothesised scale structure of the module consists of five scales (dysphagia, eating restrictions, pain, reflux and anxiety) and three single items (dry mouth, body image and hair loss).	at POD 21
Secondary	Quality of life(EORTC QLQ-C30)	Quality of life measured by EORTC QLQ-C30(Version 3)	3 months after surgery
Secondary	Quality of life(EORTC QLC STO22)	Quality of life measured by EORTC QLC STO22. The EORTC QLQ-STO 22 module contains 22 items in a similar layout and response format to the EORTC QLQ-C30. The hypothesised scale structure of the module consists of five scales (dysphagia, eating restrictions, pain, reflux and anxiety) and three single items (dry mouth, body image and hair loss).	3 months after surgery
Secondary	Quality of life(EORTC QLQ-C30)	Quality of life measured by EORTC QLQ-C30(Version 3)	12 months after surgery
Secondary	Quality of life(EORTC QLC STO22)	Quality of life measured by EORTC QLC STO22. The EORTC QLQ-STO 22 module contains 22 items in a similar layout and response format to the EORTC QLQ-C30. The hypothesised scale structure of the module consists of five scales (dysphagia, eating restrictions, pain, reflux and anxiety) and three single items (dry mouth, body image and hair loss).	12 months after surgery